Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms CPD-145 |
Target |
Action antagonists, inhibitors |
Mechanism TrkA antagonists(Nerve growth factor receptor Trk-A antagonists), TrkB inhibitors(Neurotrophic tyrosine kinase receptor type 2 inhibitors), TrkC inhibitors(Neurotrophic tyrosine kinase receptor type 3 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC42H42FN11O5 |
InChIKeyVTETXVUOPFSTLY-KWRHIPAJSA-N |
CAS Registry2412056-79-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 18 May 2020 |